Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
about
NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance statusVascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528Genetic Variants of VEGF (rs201963 and rs3025039) and KDR (rs7667298, rs2305948, and rs1870377) Are Associated with Glioma Risk in a Han Chinese Population: a Case-Control Study.Joint Effect of Urinary Total Arsenic Level and VEGF-A Genetic Polymorphisms on the Recurrence of Renal Cell Carcinoma.Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomyCommon polymorphisms in angiogenesis.Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia.High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsDetermination of VEGFR-2 (KDR) 604A>G Polymorphism in Pancreatic Disorders.Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese populationABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease.Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome.Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia.VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma.Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.
P2860
Q33417324-D4CFDCFD-6E4C-443D-94FE-A4BB344336E6Q33817641-F2FE55A6-7E74-47B5-B9C3-28F91D56A43AQ34086827-F25F348B-E023-47D7-AD01-C15DCDB0EBE4Q34322552-73A88EA3-A7C1-4389-8F32-65467ED441D1Q35669479-1473B107-2F8B-4205-93D0-D0A75393CC08Q35877762-E2C14721-4FCD-452F-A4B1-F5DDF03D46F9Q36326385-A07186ED-DC1F-4653-8A5C-F4A30633C536Q36526587-2D0B474F-F130-413B-AFE4-032B89E88370Q36546628-F9F08612-061F-406F-8D95-AF9574A3DB88Q37381574-C3F2C12F-4638-48FA-87F4-F58D0444574AQ37691036-17D52657-AD85-4A5B-ADCA-7A8C4D7AC132Q37716627-09423A7A-957D-4173-9860-9C8B20033455Q38848383-F9DEDE22-913C-4D32-A10D-71950CB86ED7Q39558408-DFCD7A77-01D8-4D58-9966-A684C3B73DDFQ40420700-015371E5-B62C-4809-A40B-866502A16E7AQ49544357-11F8C7AB-2DE3-4D01-8E48-E24646BC0F8BQ53751456-31FF1B52-26C3-44E2-88DF-A779FA49FFBAQ54276966-94FCBDEC-4F00-47A1-AA84-D7DE7E6BF884Q54320364-16D9E995-D1A2-48FB-A75D-3CC95AE69404Q54542173-D8656CB0-13A5-4AD4-AC7B-F54C88023CF8
P2860
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Clinical relevance of vascular ...... me following imatinib therapy.
@ast
Clinical relevance of vascular ...... me following imatinib therapy.
@en
Clinical relevance of vascular endothelial growth factor
@nl
type
label
Clinical relevance of vascular ...... me following imatinib therapy.
@ast
Clinical relevance of vascular ...... me following imatinib therapy.
@en
Clinical relevance of vascular endothelial growth factor
@nl
prefLabel
Clinical relevance of vascular ...... me following imatinib therapy.
@ast
Clinical relevance of vascular ...... me following imatinib therapy.
@en
Clinical relevance of vascular endothelial growth factor
@nl
P2093
P2860
P356
P1433
P1476
Clinical relevance of vascular ...... me following imatinib therapy.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDP452
P577
2009-10-29T00:00:00Z